Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04439110 · FLOW

Participant flow

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) · Source last updated 2026-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Trastuzumab Emtansine: Given IV
    id
    FG000
    title
    Treatment (Trastuzumab Emtansine)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Ineligible
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        25
      type
      Disease proression
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Alternative therapy
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Other complicating disease
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Personal reasons
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Still on treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        38
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Treatment continued until disease progression or intolerability.
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        38
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol Q, patients had to have a tumor ERBB2 copy number of \>7.
recruitment Details
Subprotocol Q was activated on August 12, 2015. A total of 58 patients were assigned to this arm after screening, all from screening cohort. Of the 58 patients, 38 patients were enrolled to arm Q between November 19, 2015 and March 20, 2017.
Complete source fields
groups
  1. description
    Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Trastuzumab Emtansine: Given IV
    id
    FG000
    title
    Treatment (Trastuzumab Emtansine)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Ineligible
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        25
      type
      Disease proression
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Alternative therapy
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Other complicating disease
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Personal reasons
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Still on treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        38
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Treatment continued until disease progression or intolerability.
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        38
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol Q, patients had to have a tumor ERBB2 copy number of \>7.
recruitment Details
Subprotocol Q was activated on August 12, 2015. A total of 58 patients were assigned to this arm after screening, all from screening cohort. Of the 58 patients, 38 patients were enrolled to arm Q between November 19, 2015 and March 20, 2017.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice